NVG-111 is a novel ROR1-CD3 bispecific antibody, targeting an oncofetal protein expressed in B-cell malignancies (mainly MCL and CLL, ALL) and acting as a receptor for the tumor growth factor Wnt5a, currently under evaluation in a first-in-human phase I trial in patients with ROR1-positive R/R MCL or CLL (NCT04763083). This evidence concerns the gene ROR1 and mantle cell lymphoma.